The stock of VolitionRX Ltd (NYSEMKT:VNRX) gapped down by $0.05 today and has $4.72 target or 11.00% below today’s $5.30 share price. The 9 months technical chart setup indicates high risk for the $123.33M company. The gap down was reported on Oct, 1 by Barchart.com. If the $4.72 price target is reached, the company will be worth $13.57M less.
Gaps down are helpful for identifying a resistance level and to could also be used as a tradeable event. If traders are short the stock and it experiece gap down, then its usually advisable to hold the short for a bigger down move. Back-tests of such patterns show that two-thirds of the these patterns the stock performance worsens after the gap. The area gaps close 91% of the time, the breakaway gaps 1%, the continuation gaps 9% and the exhaustion gaps 64%. The stock decreased 4.50% or $0.25 on September 30, hitting $5.3. About 292,358 shares traded hands or 321.09% up from the average. VolitionRX Ltd (NYSEMKT:VNRX) has risen 44.81% since February 29, 2016 and is uptrending. It has outperformed by 34.38% the S&P500.
Analysts await VolitionRX Ltd (NYSEMKT:VNRX) to report earnings on November, 2. They expect $-0.13 EPS, up 18.75% or $0.03 from last year’s $-0.16 per share. After $-0.13 actual EPS reported by VolitionRX Ltd for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
According to Zacks Investment Research, “Volition RX Ltd is a life sciences company engaged in developing a range of blood-based epigenetic cancer diagnostic tests. Its tests are designed to detect the nucleosome patterns that are specific to cancer in the blood, and identify some of the major nucleosome varieties that differ between cancer types. The Company’s development activities are primarily centered in Belgium. Volition RX Ltd is based in Singapore.”
Insitutional Activity: The institutional sentiment is 3.5 in 2016 Q2. Its the same as in 2016Q1. The ratio is the same, as 1 funds sold all VolitionRX Ltd shares owned while 1 reduced positions. only 2 funds bought stakes while 5 increased positions. They now own 6.13 million shares or 0.84% more from 6.08 million shares in 2016Q1.
Lagoda Inv Mngmt L P holds 1.9% or 1.62 million shares in its portfolio. Geode Lc last reported 63,662 shares in the company. Moreover, Creative Planning has 0% invested in VolitionRX Ltd (NYSEMKT:VNRX) for 3,200 shares. Garrison Bradford And Inc last reported 15,500 shares in the company. Southpoint Capital Advisors Limited Partnership last reported 800,000 shares in the company. Blackrock holds 0% or 1,000 shares in its portfolio. Morgan Stanley, a New York-based fund reported 51,900 shares. Tower Research Limited Liability Company (Trc) has 659 shares for 0% of their US portfolio. The New York-based Comml Bank Of New York Mellon has invested 0% in VolitionRX Ltd (NYSEMKT:VNRX). Blackrock Advisors Llc holds 1,424 shares or 0% of its portfolio. Moreover, Knoll Capital Limited Partnership has 0.47% invested in VolitionRX Ltd (NYSEMKT:VNRX) for 461,538 shares. Bank Of America Corp De, a North Carolina-based fund reported 1 shares. The New York-based Goldman Sachs Group has invested 0% in VolitionRX Ltd (NYSEMKT:VNRX). Blackrock Fund has 0% invested in the company for 2,349 shares. Natl Asset Mngmt Inc has 12,000 shares for 0.01% of their US portfolio.
More important recent VolitionRX Ltd (NYSEMKT:VNRX) news were published by: Quotes.Wsj.com which released: “VolitionRX Ltd. VNRX (US: NYSE MKT)” on May 24, 2014, also Marketwatch.com published article titled: “VolitionRX Ltd. NYSE MKT: VNRX”, Seekingalpha.com published: “VolitionRx, Ltd.: Liquid Biopsy Cancer Screening Play” on March 24, 2016. More interesting news about VolitionRX Ltd (NYSEMKT:VNRX) was released by: Prnewswire.com and their article: “VolitionRx Limited Announces Proposed Public Offering of Common Stock” with publication date: September 29, 2016.
VNRX Company Profile
VolitionRx Limited, incorporated on September 24, 1998, is a clinical-stage life sciences company. The Firm is focused on developing blood diagnostic tests for detecting and diagnosing cancer and other diseases. The Firm has developed approximately 30 blood assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company’s Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Firm is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company’s NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.